ULESFIA
LOE ApproachingNDATOPICALLOTION
Approved
Apr 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ULESFIA is a topical lotion approved in 2009 for treatment of head lice infestation. The exact mechanism of action is not publicly detailed in available data, but topical lice treatments typically work through pediculicidal or ovicidal activity. It is a small molecule formulation delivered as a non-aqueous lotion.
LOE Approaching
Product is entering loss-of-exclusivity phase with moderate competitive pressure (30%), suggesting smaller team sizes and transition focus toward retained-brand strategies or managed decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ULESFIA at this lifecycle stage means joining a team managing an established but maturing asset facing imminent generic competition. Roles focus on market defense, managed decline, and cost optimization rather than growth or launch activities.
Brand ManagerField Sales Representative
Worked on ULESFIA at Shionogi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.